Antengene Corporation Ltd. has announced a new global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in patients with advanced solid tumors. This collaboration aims to explore the efficacy of ATG-022, which has demonstrated significant activity across varying levels of Claudin 18.2 expression in gastric cancer, positioning it as a potential treatment option for a broad patient demographic. The announcement was made on May 20, 2025, highlighting Antengene's commitment to developing innovative cancer therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.